Portfolio Investments in Liquid Biopsy

About Epigenomics

Epigenomics AG, founded in 1998 and publicly listed in Frankfurt (ECX), has transitioned from a developer of its own colorectal cancer test (Epi proColon) to a pure holding company. Its mission is to manage assets and invest in companies, primarily in Germany and abroad, that are pioneering minimally invasive blood tests for cancer detection. The company's strategy leverages its legacy expertise in biomarker development and regulatory pathways to identify high-potential investment targets within the liquid biopsy sector, aiming to generate shareholder value through capital allocation rather than direct product commercialization. Recent financials indicate a significantly reduced operational loss as it executes this new strategic direction.

Therapeutic Areas

Other Early Detection of Various Cancers Drugs